AtriCure Announces the Launch of the cryoXT™ Device for Post-Operative Pain Management Following Amputation

(NASDAQ:ATRC) MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced the launch of the cryoXT™ device, an innovative cryoablation technology used to help manage post-operative pain following amputation procedures. Each year, over 185,000 amputations occur in the U.S., with approximately 60%1 of patients experiencing residual